At AAIC 2026 in London, researchers showed the PrecivityAD2 blood test helped family doctors diagnose Alzheimer's almost as accurately as specialists. Memory-clinic patients can use those results to ask focused questions about testing, scores, and next steps.
PrecivityAD2 is a blood test that measures Alzheimer's-related proteins and combines them into an amyloid probability score. The score estimates whether amyloid buildup, a hallmark of Alzheimer's, is likely present. It is meant to guide diagnosis, not replace a clinician's judgment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the Swedish study test?
- How did results change patient care?
- What do current FDA clearances allow?
- What questions can you bring to the clinic?
What did the Swedish study test?
Lund University researchers followed 1,310 patients with cognitive impairment and 165 physicians in real-world primary and specialty care. According to the Alzheimer's Association, the test measured Aβ42/40 and p-tau217 ratios as part of its amyloid probability score in its AAIC 2026 release.
Among primary-care patients, physician accuracy rose from 65% before seeing blood results to 93% after. That result nearly matched dementia specialists, who reached 94% accuracy. The gain came from adding blood biomarkers to history, exams, and cognitive testing.
How did results change patient care?
After reviewing blood results, doctors changed the Alzheimer's diagnosis in about one-third of patients. They also changed follow-up care or testing plans for more than half. Those shifts can mean different referrals, monitoring, or treatment discussions.
The test was especially useful for ruling out Alzheimer's in primary care. It helped family doctors identify patients whose impairment likely had another cause. A negative result can redirect attention to sleep problems, mood, medication effects, vascular disease, or other dementias.
What do current FDA clearances allow?
Patient Care Online reports that the FDA cleared PrecivityAD2 on Aug. 20, 2026 to aid evaluation of symptomatic adults age 40 and older in its clearance summary. Use is with clinical assessment, not as screening or a stand-alone diagnosis.
A second option followed for older adults. The FDA cleared Roche and Eli Lilly's single-biomarker Elecsys pTau217 plasma test on Aug. 25, 2026 for adults 55 and older with cognitive complaints. It is intended to help rule amyloid pathology in or out during a workup.
What questions can you bring to the clinic?
Being Patient notes that memory-clinic patients can ask whether a blood biomarker test fits their workup and what each score would change in its biomarker guide. Bring a medication list, symptom timeline, and a family member who has seen daily changes. Ask what happens if the score is intermediate and when to repeat testing or return for follow-up.
- Does a blood biomarker test fit my symptoms, age, and current workup?
- What would a negative, positive, or intermediate score mean for me?
- Will I still need PET imaging or spinal-fluid testing for confirmation?
- Should a result trigger referral for treatment, trials, counseling, or support services?
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Memory Clinic Patients Can Avoid Overreading the Headline
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: A Source-Checked Briefing for Memory Clinic Patients
- The NIA 2026 Dementia Care and Caregiving Summit Report: Questions Working Dementia Caregivers Can Ask Local Care Programs
